TherapeuticsMD extends loan maturity to July 27, appoints CRO, explores Chapter 11

TherapeuticsMD, Inc.

Amendment No. 13 extends Financing Agreement maturity to July 27, 2022.
Company pays Lenders $2.9 million interest payment as part of amendment.
Jeffrey Varsalone of G2 Capital Advisors appointed as Chief Restructuring Officer.
Board evaluating all options including refinancing, strategic alternatives, and Chapter 11.
Company intends to maintain normal operations while evaluating options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.